Cargando…

Second-Generation SARS-CoV-2 Recombinants: Lessons from Other Viruses

Detalles Bibliográficos
Autores principales:	Focosi, Daniele, Maggi, Fabrizio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221267/ https://www.ncbi.nlm.nih.gov/pubmed/37243149 http://dx.doi.org/10.3390/v15051063

Ejemplares similares

Recombination in Coronaviruses, with a Focus on SARS-CoV-2
por: Focosi, Daniele, et al.
Publicado: (2022)

SARS-CoV-2: Advances in Serological Methods and the Understanding of Antibody Escape
por: Focosi, Daniele, et al.
Publicado: (2023)

How SARS-CoV-2 Big Data Are Challenging Viral Taxonomy Rules
por: Focosi, Daniele, et al.
Publicado: (2023)

SARS-CoV-2 recombinant XN, Italy
por: Novazzi, Federica, et al.
Publicado: (2022)

SARS-CoV-2 BA.2.86 (“Pirola”): Is it Pi or Just Another Omicron Sublineage?
por: Focosi, Daniele, et al.
Publicado: (2023)

Spike mutations in SARS-CoV-2 AY sublineages of the Delta variant of concern: implications for the future of the pandemic
por: Focosi, Daniele, et al.
Publicado: (2022)

SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies
por: Focosi, Daniele, et al.
Publicado: (2021)

Respiratory delivery of passive immunotherapies for SARS-CoV-2 prophylaxis and therapy
por: Focosi, Daniele, et al.
Publicado: (2023)

Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence
por: Focosi, Daniele, et al.
Publicado: (2022)

Antibodies and SARS-CoV-2: New Data on Diagnostics and Therapeutics
por: Focosi, Daniele, et al.
Publicado: (2022)

From Co-Administration to Co-Formulation: The Race for New Vaccines against COVID-19 and Other Respiratory Viruses
por: Focosi, Daniele
Publicado: (2023)

Expansion of L452R-Positive SARS-CoV-2 Omicron Variant, Northern Lombardy, Italy
por: Novazzi, Federica, et al.
Publicado: (2022)

Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline
por: Tuccori, Marco, et al.
Publicado: (2020)

Anti-SARS-CoV-2 RBD IgG responses in convalescent versus naïve BNT162b2 vaccine recipients
por: Azzi, Lorenzo, et al.
Publicado: (2021)

Analysis of SARS-CoV-2 sublineages reported from local cases in mainland China (September 2022-January 2023) and surveillance of outbound passengers.
por: Focosi, Daniele, et al.
Publicado: (2023)

SARS-CoV-2 tracking in Tunisia through next-generation sequencing: lessons for the future
por: Rebai, Ahmed, et al.
Publicado: (2021)

SARS-CoV-2 infection, vaccination and acquired hemophilia: Reply
por: Franchini, Massimo, et al.
Publicado: (2023)

Sotrovimab-emergent resistance in SARS-CoV-2 Omicron: A series of three cases
por: Focosi, Daniele, et al.
Publicado: (2022)

Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses
por: Nguyen, Tuan M., et al.
Publicado: (2020)

Co-detection of SARS-CoV-2 and other respiratory pathogens: Lessons from the field to face the second wave
por: Muggeo, Anaëlle, et al.
Publicado: (2020)

SARS-CoV-2 in the U.S. Military — Lessons for Civil Society
por: Michael, Nelson L.
Publicado: (2020)

SARS-CoV-2 and other pathogenic microorganisms in the environment
por: Núñez-Delgado, Avelino, et al.
Publicado: (2021)

SARS-CoV-2: Immunopeptidomics and Other Immunological Studies
por: Chavda, Vivek P., et al.
Publicado: (2022)

Lessons from the Nationwide Surveillance of SARS-CoV-2 Surges in Japan
por: Seki, Masafumi
Publicado: (2021)

TTV viral load as a predictor of antibody response to SARS COV-2 vaccination
por: Focosi, Daniele, et al.
Publicado: (2023)

Nicotine upregulates ACE2 expression and increases competence for SARS-CoV-2 in human pneumocytes
por: Maggi, Fabrizio, et al.
Publicado: (2021)

SARS CoV-2 (COVID-19): lessons to be learned by Brazilian Physical Therapists
por: Pinto, Thiago Fernandes, et al.
Publicado: (2020)

Monoclonal antibody therapies against SARS-CoV-2
por: Focosi, Daniele, et al.
Publicado: (2022)

Prescription of Anti-Spike Monoclonal Antibodies in COVID-19 Patients with Resistant SARS-CoV-2 Variants in Italy
por: Focosi, Daniele, et al.
Publicado: (2022)

SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern
por: Casadevall, Arturo, et al.
Publicado: (2023)

Spike protein evolution in the SARS-CoV-2 Delta variant of concern: a case series from Northern Lombardy
por: Baj, Andreina, et al.
Publicado: (2021)

Breakthrough Infections of E484K-Harboring SARS-CoV-2 Delta Variant, Lombardy, Italy
por: Baj, Andreina, et al.
Publicado: (2021)

Detection of Torquetenovirus and Redondovirus DNA in Saliva Samples from SARS-CoV-2-Positive and -Negative Subjects
por: Spezia, Pietro Giorgio, et al.
Publicado: (2022)

Association between SARS-CoV-2 infection or vaccination and acquired hemophilia A: A case report and literature update
por: Franchini, Massimo, et al.
Publicado: (2023)

Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains
por: Padron-Regalado, Eriko
Publicado: (2020)

SARS-CoV-2 Re-infections: Lessons from Other Coronaviruses
por: van der Hoek, Lia
Publicado: (2020)

Generation and transmission of interlineage recombinants in the SARS-CoV-2 pandemic
por: Jackson, Ben, et al.
Publicado: (2021)

Viral pandemics and oral health: Lessons learned from HIV to SARS-CoV-2
por: Patton, Lauren L.
Publicado: (2021)

Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis
por: Focosi, Daniele, et al.
Publicado: (2022)

Lessons Learned From the MERS-CoV Outbreak
por: Sutton, Nadia R., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t5fhiavj80heack1l0v0hoogpt